MedTrace Logo

Nimotuzumab in Children With Intrinsic Pontine Glioma

NCT00561691 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 41

Last updated 2013-03-29

No results posted yet for this study

Summary

Determination of efficiency of nimotuzumab in children with diffuse intrinsic pontine glioma.

Conditions

  • Diffuse Instrinsic Ponitine Glioma

Interventions

DRUG

nimotuzumab

monoclonal antibody

Sponsors & Collaborators

  • Children's Medical Hospital, University of Bonn, Germany

    collaborator OTHER

  • University of Wuerzburg

    collaborator OTHER

  • Dept. of Statistics, University of Dortmund, Germany

    collaborator OTHER

  • CRM Biometrics GmbH

    collaborator INDUSTRY

  • Heinrich-Heine University, Duesseldorf

    collaborator OTHER

  • Dr. von Haunersches Children's Medical Hospital, University of Munich, Germany

    collaborator OTHER

  • Children's Medical Hospital, University of Homburg/Saar, Homburg/Saar, Germany

    collaborator OTHER

  • Children's Medical Hospital, Medical School Hannover, Hannover, Germany

    collaborator UNKNOWN

  • Children's Medical Hospital, University of Leipzig, Leipzig, Germany

    collaborator OTHER

  • Children's Medical Hospital, University of Muenster, Muenster, Germany

    collaborator OTHER

  • Burdenko Neurosurgery Institute

    collaborator OTHER

  • Istituto Nazinonale Tumori, Div. of Paediatric Oncology,Milano, Italy

    collaborator UNKNOWN

  • Oncoscience AG

    lead INDUSTRY

Principal Investigators

  • Udo Bode, Prof. MD · University Bonn

Eligibility

Min Age
3 Years
Max Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-04-30
Completion
2012-01-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00561691 on ClinicalTrials.gov